Correlation Between Eliem Therapeutics and Krystal Biotech

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Eliem Therapeutics and Krystal Biotech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eliem Therapeutics and Krystal Biotech into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Eliem Therapeutics and Krystal Biotech, you can compare the effects of market volatilities on Eliem Therapeutics and Krystal Biotech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eliem Therapeutics with a short position of Krystal Biotech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eliem Therapeutics and Krystal Biotech.

Diversification Opportunities for Eliem Therapeutics and Krystal Biotech

0.33
  Correlation Coefficient

Weak diversification

The 3 months correlation between Eliem and Krystal is 0.33. Overlapping area represents the amount of risk that can be diversified away by holding Eliem Therapeutics and Krystal Biotech in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Krystal Biotech and Eliem Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eliem Therapeutics are associated (or correlated) with Krystal Biotech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Krystal Biotech has no effect on the direction of Eliem Therapeutics i.e., Eliem Therapeutics and Krystal Biotech go up and down completely randomly.

Pair Corralation between Eliem Therapeutics and Krystal Biotech

Given the investment horizon of 90 days Eliem Therapeutics is expected to under-perform the Krystal Biotech. In addition to that, Eliem Therapeutics is 1.62 times more volatile than Krystal Biotech. It trades about -0.29 of its total potential returns per unit of risk. Krystal Biotech is currently generating about 0.17 per unit of volatility. If you would invest  17,689  in Krystal Biotech on August 29, 2024 and sell it today you would earn a total of  1,963  from holding Krystal Biotech or generate 11.1% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy90.91%
ValuesDaily Returns

Eliem Therapeutics  vs.  Krystal Biotech

 Performance 
       Timeline  
Eliem Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Eliem Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.
Krystal Biotech 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Krystal Biotech are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable basic indicators, Krystal Biotech is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.

Eliem Therapeutics and Krystal Biotech Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Eliem Therapeutics and Krystal Biotech

The main advantage of trading using opposite Eliem Therapeutics and Krystal Biotech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eliem Therapeutics position performs unexpectedly, Krystal Biotech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Krystal Biotech will offset losses from the drop in Krystal Biotech's long position.
The idea behind Eliem Therapeutics and Krystal Biotech pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Other Complementary Tools

My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Commodity Directory
Find actively traded commodities issued by global exchanges
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities